Anyhydrous compositions of mTOR inhibitors and methods of use
Disclosed herein are compositions and methods for topical delivery of mTOR inhibitors. In one embodiment, an anhydrous composition includes one or more mTOR inhibitors, one or more solvents, one or more gelling agents, and one or more antioxidants. Also disclosed herein are methods to treat skin disorders using such compositions.
1. A method of treating a skin disorder in a subject in need thereof comprising topically administering to the subject an anhydrous gel composition, wherein the anhydrous gel composition comprises
2.5 wt % to about 4.5 wt % of rapamycin or a pharmaceutically acceptable salt thereof, based upon the total weight of the composition,
about 80 wt % to about 97 wt % of a solvent, based upon the total weight of the composition, wherein the solvent is about 1 wt % to about 30 wt % diisopropyl adipate based upon the total weight of the composition, about 1 wt % to about 30 wt % glycerol based upon the total weight of the composition, about 40 wt % to about 60 wt % polyethylene glycol based upon the total weight of the composition, and about 1 wt % to about 30 wt % isopropyl alcohol, based upon the total weight of the composition,
about 0.1 wt % to about 5 wt % of a gelling agent, based upon the total weight of the composition,
about 0.001 wt % to about 1 wt % of an antioxidant, based upon the total weight of the composition, and optionally an additional pharmaceutically acceptable excipient,
wherein a total weight of the composition is 100 wt %,
wherein the anhydrous gel composition has a pH of about 4 to about 6, and
wherein the skin disorder is selected from the group consisting of pachyonychia congenita, basal cell nevus syndrome, and angiofibromas.
2. The method of claim 1 , wherein the skin disorder is pachyonychia congenita.
3. The method of claim 1 , wherein the skin disorder is angiofibroma.
4. The method of claim 2 , wherein treating pachyonychia congenita is treating a symptom of pachyonychia congenita selected from pain, itch, or a combination thereof.
5. The method of claim 1 , wherein the anhydrous gel composition further comprises a polymeric surfactant, a moisturizing agent, a cooling agent, a rheology modifier, a non-aqueous pH adjusting agent, a preservative, and combinations thereof.
6. The method of claim 1 , wherein the gelling agent is selected from the group consisting of hydroxypropyl cellulose, carbomer 981, carbomer 934P, glyceryl tris 12-hydroxy stearate, hydroxy stearin, propylene carbonate, polyvinyl pyrrolidine, and combinations thereof.
7. The method of claim 1 , wherein the antioxidant is selected from the group consisting of ascorbyl palmitate, propyl gallate, α-tocopherol, and combinations thereof.
8. The method of claim 1 , wherein the anhydrous gel composition further comprises a skin care agent selected from the group consisting of cis-retinoic acid, trans-retinoic acid, retinol, retinyl esters, and combination thereof.
9. The method of claim 1 , wherein the anhydrous gel composition comprises:
rapamycin from about 3 wt % to about 4.5 wt % of the composition;
polyethylene glycol from about 40 wt % to about 60 wt % of the composition;
isopropyl alcohol at about 15 wt % of the composition;
diisopropyl adipate at about 15 wt % of the composition;
glycerol at about 10 wt % of the composition;
wherein the gelling agent is hydroxypropyl cellulose from about 0.1 wt % to about 1 wt % of the composition;
an antioxidant from about 0.001 wt % to about 0.1 wt % of the composition; and
an additional pharmaceutically acceptable excipient that is a buffer.
10. The method of claim 1 , wherein the anhydrous gel composition comprises:
rapamycin at about 3.9 wt % of the composition;
isopropyl alcohol at about 15 wt % of the composition;
polyethylene glycol at about 55.3 wt % of the composition;
diisopropyl adipate at about 15 wt % of the composition;
glycerol at about 10 wt % of the composition;
wherein the gelling agent is hydroxypropyl cellulose;
wherein the antioxidant is propyl gallate, ascorbyl palmitate, and alpha-tocopherol; and
an additional pharmaceutically acceptable excipient that is a buffer.
11. The method of claim 1 , wherein the anhydrous gel composition has a pH of about 4.5 to about 5.
12. The method of claim 1 , wherein the anhydrous gel composition has a viscosity of about 5000 cP to about 20,000 cP.
13. The method of claim 1 , wherein the anhydrous gel composition is administered to the subject once daily, twice daily or three times a day.
14. The method of claim 1 , wherein the skin disorder is basal cell nevus syndrome.
15. The method of claim 1 , wherein the anhydrous gel composition is administered to the subject once daily or twice daily.
16. The method of claim 1 , wherein the anhydrous gel composition is administered for at least 3 months.
17. The method of claim 1 , wherein the rapamycin or pharmaceutically acceptable salt thereof is stable in the anhydrous gel composition at a temperature of about 4° C. to about 40° C. for a period of 12 to 36 months.
18. A method of treating pachyonychia congenita in a subject in need thereof comprising topically administering once or twice daily to the subject an anhydrous gel composition, wherein the anhydrous gel composition comprises
2.5 wt % to about 4.5 wt % of rapamycin or a pharmaceutically acceptable salt thereof, based upon the total weight of the composition,
about 80 wt % to about 97 wt % of a solvent, based upon the total weight of the composition, wherein the solvent is about 15% diisopropyl adipate based upon the total weight of the composition, about 10% glycerol based upon the total weight of the composition, about 55% polyethylene glycol based upon the total weight of the composition, and about 15% isopropyl alcohol, based upon the total weight of the composition,
about 0.1 wt % to about 5 wt % of a gelling agent, based upon the total weight of the composition,
about 0.001 wt % to about 1 wt % of an antioxidant, based upon the total weight of the composition, and
optionally an additional pharmaceutically acceptable excipient,
wherein a total weight of the composition is 100 wt %,
wherein the pH of the anhydrous gel composition is about 4 to about 6.
19. The method of claim 18 , wherein treating pachyonychia congenita is treating a symptom of pachyonychia congenita selected from pain, itch, or a combination thereof.
20. The method of claim 18 , wherein the anhydrous gel composition further comprises a polymeric surfactant, a moisturizing agent, a cooling agent, a rheology modifier, a non-aqueous pH adjusting agent, a preservative, and combinations thereof.
21. The method of claim 18 , wherein the gelling agent is selected from the group consisting of hydroxypropyl cellulose, carbomer 981, carbomer 934P, glyceryl tris 12-hydroxy stearate, hydroxy stearin, propylene carbonate, polyvinyl pyrrolidine, and combinations thereof.
22. The method of claim 18 , wherein the antioxidant is selected from the group consisting of ascorbyl palmitate, propyl gallate, α-tocopherol, and combinations thereof.
23. The method of claim 18 , wherein the anhydrous gel composition further comprises a skin care agent selected from the group consisting of cis-retinoic acid, trans-retinoic acid, retinol, retinyl esters, and combination thereof.
24. The method of claim 18 , wherein the anhydrous gel composition comprises:
rapamycin from about 3 wt % to about 4.5 wt % of the composition;
polyethylene glycol at about 55% of the composition;
isopropyl alcohol at about 15 wt % of the composition;
diisopropyl adipate at about 15 wt % of the composition;
glycerol at about 10 wt % of the composition;
wherein the gelling agent is hydroxypropyl cellulose from about 0.1 wt % to about 1 wt % of the composition;
an antioxidant from about 0.001 wt % to about 0.1 wt % of the composition; and
an additional pharmaceutically acceptable excipient that is a buffer.
25. The method of claim 18 , wherein the anhydrous gel composition comprises:
rapamycin at about 3.9 wt % of the composition;
isopropyl alcohol at about 15 wt % of the composition;
polyethylene glycol at about 55.3 wt % of the composition;
diisopropyl adipate at about 15 wt % of the composition;
glycerol at about 10 wt % of the composition;
wherein the gelling agent is hydroxypropyl cellulose;
wherein the antioxidant is propyl gallate, ascorbyl palmitate, and alpha-tocopherol at about 0.002 wt % of the composition; and
an additional pharmaceutically acceptable excipient that is a buffer.
26. The method of claim 18 , wherein the anhydrous gel composition has a viscosity of about 5000 cP to about 20,000 cP.
27. The method of claim 18 , wherein the anhydrous gel composition is administered to the subject twice daily.
28. The method of claim 18 , wherein the anhydrous gel composition is administered for at least 3 months.
29. The method of claim 18 , wherein the rapamycin or pharmaceutically acceptable salt thereof is stable in the anhydrous gel composition at a temperature of about 4° C. to about 40° C. for a period of 12 to 36 months.